Abstract
Graphical Abstract Overview of study design. Metagenomic and plasma/fecal metabolomic studies were performed in 44 NSCLC patients who underwent neoadjuvant tislelizumab therapy plus platinum-based doublet chemotherapy.
Cite
CITATION STYLE
APA
Cao, A., Lin, Y., Guan, S., Chen, Y., Zhai, W., Zhou, Y., … Long, H. (2026). Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer. Clinical and Translational Medicine, 16(1). https://doi.org/10.1002/ctm2.70579
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free